Ind-Swift Laboratories Limited (NSE:INDSWFTLAB)

Market Cap	19.45B +155.4%
Revenue (ttm)	6.41B +14.2%
Net Income	414.15M -83.5%
EPS	4.84 -86.3%
Shares Out	86.71M
PE Ratio	46.34
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	446,216
Open	220.79
Previous Close	219.82
Day's Range	215.00 - 227.30
52-Week Range	87.15 - 248.45
Beta	0.71
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About Ind-Swift Laboratories

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson’s disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticance...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 1,246
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: INDSWFTLAB

Financial Performance

In fiscal year 2026, Ind-Swift Laboratories's revenue was 6.41 billion, an increase of 14.17% compared to the previous year's 5.62 billion. Earnings were 414.15 million, a decrease of -83.47%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 31, 2026

Data Sources Report a data error